Product Overview
The improved Instanosis 3-in-1 Fentanyl, Xylazine, and Medetomidine Test Kit is a sensitive, NIH-funded lateral flow assay designed for forensic and harm reduction applications. Manufactured in the USA, this advanced screening tool simultaneously identifies three major illicit substances on a single strip, utilizing highly specific analytical cut-offs: 100 ng/mL for fentanyl, 20 ng/mL for xylazine, and 150 ng/mL for medetomidine. Tools are provided for convenient sample preparation.
Technical Specifications & Key Data
This multi-drug immunoassay is explicitly engineered to address highly complex polysubstance configurations within the illicit supply chain:
-
Multiplexed Detection Profile: Screens for Fentanyl, Xylazine, and Medetomidine simultaneously. Cross react with many drug analogs.
-
Analytical Limits of Detection (LOD):
-
Fentanyl: 100 ng/mL
- Carfentanl: 2,000 ng/mL
-
Xylazine: 20 ng/mL
- 4-hydroxy xylazine: 20 ng/mL
-
Medetomidine: 150 ng/mL
- Detomidine: 150 ng/mL
- Dexmedetomidine: 150 ng/mL
- Levamedetomidine: 10,000 ng/mL
-
-
Sample Preparation: Included tools enable quick and easy sample preparation from various sample types and formats.
-
Quality & Funding Benchmarks: Developed under strict FDA QMSR quality control standards via National Institutes of Health (NIH) grant funding and proudly Made in the U.S.
Public Health & Epidemiological Context
The introduction of medetomidine (an alpha-2 adrenergic receptor agonist approved strictly for veterinary sedation) represents a critical shift in the synthetic opioid crisis (Zhu et al, Lancet Reg Health Am, 2025).
-
High Potency Threat: Medetomidine exhibits an overall clinical potency 200- to 300-fold greater than xylazine, substantially escalating the risk of profound sedation, bradycardia, and severe respiratory depression.
-
Co-Adulteration Prevalence: Federal public health tracking indicates that approximately 98% of illegal drug samples testing positive for medetomidine are co-adulterated with fentanyl (CDC Health Alert Network).
-
Geographic Vulnerability: Sentinel site surveillance and wastewater testing programs have confirmed rapid geographic expansion, tracking heavy clusters across the Northeast, Midwest, and Southern United States (CDC Health Alert Network).
Frequently Asked Questions (FAQ)
-
Q1: What substances does this specific Instanosis 3-in-1 test strip screen for?
A: This specific immunoassay simultaneously screens for Fentanyl, Xylazine (a common sedative adulterant), and Medetomidine (a highly potent emerging synthetic sedative often referred to on the street as “rhino tranq”), all using a single sample application.
-
Q2: What are the exact analytical cut-off levels for the strip?
A: The precise technical cut-off levels are engineered at 100 ng/mL for fentanyl, 20 ng/mL for xylazine, and 150 ng/mL for medetomidine. This provides greater sensitivity than historical standard test strips that often default to a 1,000 ng/mL threshold.
-
Q3: Why is tracking medetomidine considered a public health priority?
A: Medetomidine is roughly 200 to 300 times more potent than xylazine (Zhu et al, Lancet Reg Health Am, 2025). Because it causes severe, prolonged central nervous system depression and bradycardia that cannot be directly reversed by naloxone alone, field checking tools are vital for harm reduction teams to alert local populations.
-
Q4: How does this product handle the chiral properties of medetomidine?
A: Illicit medetomidine typically appears in the field as a racemic mixture of different enantiomers. While some brands fail to detect certain variations, the Instanosis strip features a formulation that recognizes both chemical isomers to prevent false negatives.
-
Q5: Is this product intended for clinical patient diagnostics?
A: No. This product is strictly labeled and intended for forensic investigations, harm reduction surveillance, and laboratory research applications only.
Click to download Instanosis 3-in-1 fentanyl/xylazine/medetomidine test kit instruction
